Koshy AG, Kim HT, Liegel J, et al. Phase II Clinical Trial Evaluating Abatacept in Patients with Steroid-Refractory Chronic Graft versus Host Disease. Blood. 2023; (doi: 10.1182/blood.2022019107).

Treatment with abatacept, a selective co-stimulation modulator, resulted in a 58% overall response rate among patients with steroid-refractory chronic graft versus host disease (cGVHD), according to recent study results. The Phase II clinical trial, which evaluated the efficacy of abatacept for the treatment of steroid-refractory cGVHD, observed a partial response in all responders. Patients tolerated the drug well, and treatment resulted in a sustained reduction in the dose of prednisone. Interleukin-1 alpha, interleukin-21, tumor necrosis factor-alpha, and PD-1 expression by CD4+ T cells decreased in all patients following treatment with abatacept, according to immune correlative studies. The study results highlight the drug's potential as a therapeutic option in treating cGVHD.

Read More

Tags: GVHD, HCT, transplantation, Cellular therapy, Research, Transplant, disease, cGVHD, cell therapy, chronic GVHD, graft-versus-host disease, graft-vs-host disease, graft-versus-host